Healthcare Industry News: HSMN NewsFeed
News Release - May 22, 2017
Bluejay Diagnostics' Board Of Directors Announces Appointment Of Douglas C. Wurth As ChairmanACTON, Mass., May 22, 2017 -- (Healthcare Sales & Marketing Network) -- Bluejay Diagnostics, Inc. (Bluejay) today announced that its board of directors unanimously named Douglas C. Wurth as the Company's chairman, effective immediately.
Mr. Wurth recently retired from J.P. Morgan Chase after a successful 19-year career with the Firm, where he was the Chief Executive Officer of Alternative Investments for J.P. Morgan Asset Management. In this role, he led JP Morgan's Global Real Assets, Private Equity, J.P. Morgan Alternative Asset Management Hedge Fund Solutions, Highbridge Capital Management and Gávea businesses. He previously served as Chief Executive Officer of J.P. Morgan's International Private Bank based out of Hong Kong, London, and New York. In this capacity, Mr. Wurth oversaw the expansion of the franchise outside of the United States, ultimately responsible for over $80 billion of assets. Prior to this role, he was the global head of J.P. Morgan Private Bank's Alternative Investments Group, which supervised over $35 billion of alternative investments, including hedge funds, private equity and real estate. Mr. Wurth began working in J.P. Morgan's Mergers & Acquisition group in 1997 and joined the Private Bank in 1999. Prior to joining J.P. Morgan, Mr. Wurth practiced law at the New York firm Skadden, Arps, Slate, Meagher & Flom, and served as General Counsel to former U.S. Senator Robert Dole's 1996 presidential campaign.
"We are delighted to welcome Mr. Wurth as Bluejay's chairman," said Donald R. Chase, member of the Bluejay Board of Directors. "Mr. Wurth is an exceptionally talented executive with a truly global perspective, who has a proven track record of strong strategic business leadership. His acumen, business network, and experience will augment the Company's path forward as a leader in the development and application of medical diagnostic technology, which addresses global healthcare challenges."
"I am gratified to help lead Bluejay – a great company with a mission-based goal of saving and improving the lives of those who may not have access to affordable healthcare," said Mr. Wurth. "I admire Bluejay's determination to advance healthcare through innovation, and to help provide the general public with unparalleled innovative and affordable care. Bluejay's growing international footprint and unmatched capabilities through its global partners, offer enormous opportunities to improve the health of millions of people worldwide. I look forward to working with the Bluejay team as they continue to advance the Company as a healthcare leader."
"Mr. Wurth brings his substantial business and finance background, and proven strategic leadership to the role of Chairman of Bluejay's Board of Directors," said Svetlana Dey, Bluejay's President and CEO. "The Board joins me in thanking Mr. Wurth for accepting the position of Chairman of the Board."
Mr. Wurth is a graduate of the University of Notre Dame (B.A.) and the University of Virginia School of Law (J.D.). He resides in New York City, and is on the boards of the American Ballet Theatre and the American Friends of the Serpentine Museum.
About Bluejay Diagnostics, Inc.
Bluejay Diagnostics, Inc., headquartered in Acton, Massachusetts, is a clinical stage diagnostic company focused on the development, manufacturing, sales, and marketing of non-invasive, point-of-care ("POC") tests and devices that provide patients and providers with access to affordable and timely healthcare. The Company's flagship product, a POC test for Allergic Conjunctivitis, Allereye™ is currently undergoing U.S. FDA 510(k) clinical trials with an expected launch in late 2017.
Any forward-looking statements are subject to risks and uncertainties. Actual results may differ materially from anticipated results.
Source: Bluejay Diagnostics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.